<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683680</url>
  </required_header>
  <id_info>
    <org_study_id>18-220</org_study_id>
    <secondary_id>CA120528</secondary_id>
    <nct_id>NCT03683680</nct_id>
  </id_info>
  <brief_title>Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers</brief_title>
  <official_title>Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating a new method for determining stage and prognosis of
      individuals with malignant pleural mesothelioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to test a new method for determining the stage and
      prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to
      accurately determine cancer stage prior to surgery or another treatment. This new method may
      allow doctors to better classify cancer stage and give a better estimate for prognosis prior
      to surgery or another treatment.

      In this research study, the investigators would like to use biopsied tissue to study certain
      characteristics that will help test the new method for determining cancer stage and
      estimating prognosis.

      In this research study, the investigators are...

        -  Obtaining pleural specimens at the time of routine diagnostic biopsy during the
           participant's standard treatment.

        -  Storing your biopsied tissue

        -  Studying the tissue to determine if the new method of staging and prognosis is accurate
           and valid
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-treatment Prognostic Algorithm Validation</measure>
    <time_frame>4 years</time_frame>
    <description>The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will be assigned to each patient and the data will be analyzed by a statistician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Molecular Tests Base on RNA Expression</measure>
    <time_frame>4 years</time_frame>
    <description>The secondary objective is to develop new molecular signatures for distinct clusters of mesothelioma samples grouped according to their gene expression. RNA expression data will be compared between one cluster and all the other clusters and using a variety of statistical and bioinformatics tools. Two-hundred sixteen MPM cases with available RNAseq data will be divided into training and test sets to develop and test potential signatures. The signatures that define each cluster with high sensitivity and specificity will then be tested using RTPCR in a cohort of 555 prospective-collected samples.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>MRiS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The specimens to be collected will include at least five pleural biopsy samples
MPT test and the CLDN15/VIM test will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MPT Test</intervention_name>
    <description>molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms</description>
    <arm_group_label>MRiS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CLDN15/VIM Test</intervention_name>
    <description>molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms</description>
    <arm_group_label>MRiS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients with a diagnosis of malignant pleural mesothelioma undergoing

               -  diagnostic pleural biopsy

               -  pleuroscopy

               -  and/or VATS resections

          -  Participants must be 18 years of age or older.

        Exclusion Criteria:

        -Any patient who is found to be unsuitable for

          -  surgery,

          -  treatment

          -  diagnosis,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Bueno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphael Bueno, MD</last_name>
    <phone>617-732-5690</phone>
    <email>rbueno@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael Bueno, MD</last_name>
      <phone>617-732-5690</phone>
      <email>rbueno@partners.org</email>
    </contact>
    <investigator>
      <last_name>Raphael Bueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Raphael Bueno, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

